Cerus Corporation Overview
Pro stress-test →Cerus Corporation operates as a biomedical products company focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is a proprietary technology designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Strategic Profile
Pro stress-test →The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The company operates on a B2B model targeting blood centers, hospitals, and healthcare providers, generating revenue through the sale of INTERCEPT Blood System products, service contracts, and licensing agreements.
Competitive Landscape
Pro stress-test →Haemonetics Corporation competes with Cerus in certain blood management product categories. Macopharma, a European company, provides blood processing and pathogen inactivation solutions. Several startups are developing innovative blood safety technologies, posing potential threat to Cerus's market share.
Industry Context
Cerus Corporation operates in Medical Devices - Blood Safety & Pathogen Reduction Technologies.
Key facts
Founded: 1991 · Headquarters: Concord, California, United States · Employees: 281 · Revenue: $201.3M · Market cap: $311.2M